a protein of 12,000 mol wt found in cytosol of intestinal mucosa and other tissues, which exhibits high affinity for long chain fatty acids. It has been suggested that FABP (which may comprise a group of closely related proteins of 12,000 mol wt) participates in cellular fatty acid transport and metabolism. Although earlier findings were consistent with this concept, the present studies were designed to examine its physiological function more directly.
INTRODUCTION
The cytosol of rat and human intestinal mucosa, liver, myocardium, kidney, and adipose tissue contains one or more proteins of 12,000-mol wt designated fatty acid binding protein (FABP)' which exhibit high affinity for long chain fatty acids (1) (2) (3) . Hepatic FABP appears closely related to the Z protein of Levi et al. (4), also shown to bind long chain fatty acids (5). We proposed that intestinal FABP participates in the intracellular transport of fatty acid, and that its counterparts in other tissues play a similar role (1) .
in crypts, and in mucosa from proximal and mid-jejunoileum than from distal. Mucosal FABP concentrations were significantly higher in animals maintained on high fat diets than in those on low fat diets. After intraluminal administration, [3H]palmitate was recovered in the FABP fraction of mucosal cytosol.
These findings were consistent with a role for FABP in cellular fatty acid transport, but because the evidence was indirect, additional experimental approaches were required.
Fatty acid uptake by the intestine and other cells is passive; fatty acids appear to interact with plasma membrane lipids, and no specific receptors have been demonstrated (6) (7) (8) (9) (10) . It was postulated that FABP facilitates the desorption of fatty acid from the inner aspect of the membrane, and that the fatty acid-FABP complex diffuses to the endoplasmic reticulum where the fatty acid is activated to its coenzyme A thioester. If this concept is correct, agents which inhibit the binding of fatty acids to FABP should, thereby, inhibit activation and esterification in everted gut sacs, but should have a lesser effect on initial uptake.
Two compounds which inhibit binding of fatty acid to hepatic Z protein are flavaspidic acid-N-methyl-glucaminate' and a-bromopalmitate (11) . The latter was shown by earlier investigators to inhibit fatty acid oxidation in perfused heart muscle (12) and isolated hepatocytes (13) ; the oxidation of medium chain fatty acid was not affected (13) , while that of glucose was enhanced (12) . In 1971, Mehadevan and Sauer concluded that a-bromopalmitate exerted its effect by competing for an as yet unrecognized cellular transport system for long chain fatty acids (13) .
In the present studies, flavaspidic acid and a-bromopalmitate, structurally dissimilar compounds which are not known to be metabolized in the intestine, were shown to inhibit the binding of oleate to partially purified intestinal FABP, and were employed with preparations of rat intestine in experiments designed to test the proposed function of this protein. The results provide additional support for the hypothesis, and also suggest that FABP may play a broader role in cellular fatty acid metabolism. Portions of these studies were included in a preliminary communication (3) . land. Unlabeled oleic acid, glycerol-1-monooleate, and sodium taurocholate were purchased from Calbiochem, San Diego, Calif. Egg lecithin and defatted bovine serum albumin were purchased from Schwarz/Mann, Div., Becton, Dickinson & Co., Orangeburg, N. Y.; the albumin was delipidated further by the method of Chen (14) . Egg lecithin and glycerol monooleate were purified by silicic acid chromatography (15 Partial purification of intestinal FABP and in vitro bindinig studies. Intestinal FABP was partially purified as the fraction of 12,000 mol wt from intestinal mucosal 105,000-g supernate on Sephadex G-50, as previously described (1) . Three batches of this material, the "FABP fraction," contained 23.1±2.6% (SEM) FABP, as determined by quantitative radial immunodiffusion (2) . For semiquantitative estimates of binding of ["C]oleate and flavaspidic acid, ligands dissolved in 8,l methyl ethyl ketone or in 50 Al 50% propylene glycol were added to 1.0 ml FABP fraction (0.5 mg/ml) and were subjected to nonequilibrium Sephadex G-25 column gel filtration (1) .
Studies of everted jejunal sacs. Studies were performed as described and standardized previously (16 (17) showed that at 4 min, correction for adherent fluid in studies with long chain fatty acid in mixed micelles was not essential. In the experiments in which conversion of ["C] -oleate, ['4C]acetate, and ["C]glucose to "CO2 was measured, sacs were incubated under identical conditions in flasks fitted with a center well. At the conclusion of the incubation, 0.4 ml Hydroxide of Hyamine (Packard Instrument Co., Inc., Downers Grove, Ill.) was added to the center well, and the contents of the flasks were acidified with 0.2 ml of 8 M sulfuric acid. "CO2 was collected during an additional 30-min incubation, and the contents of the center well were assayed for radioactivity. In some experiments, incorporation of ["C]glucose into the glycerol and fatty acid moieties of mucosal phospholipids and triglycerides was measured.
Sacs incubated for 4 min in mixed micellar solutions, with or without flavaspidic acid or a-bromopalmitate, were examined histologically. No significant differences were observed, consistent with the earlier observation that flavaspidic acid was not toxic to liver tissue (18 37°C , and were terminated by the addition of 2 ml 95%o ethanol followed by 0.5 ml 6 N HCI. Hydroxamates were extracted from the precipitate with petroleum ether and dried under Na; color was developed with the Hill reagent (23) and read at 520 nm. Hydroxamate formation was calculated on the basis of molar absorbancy, E = 1,000 (22) .
Analytical procedures. Lipids were extracted by the method of Folch et al. (24) . Lipid classes were separated by thin-layer chromatography on 0.25-mm silica gel H, and identified as described previously (16) . Appropriate zones were scraped directly into counting vials and assayed for radioactivity, or were eluted for subsequent quantification.
Flavaspidic acid-N-methyl-glucaminate, readily identified by its bright yellow color, was chromatographically pure in the above thin-layer chromatography system, in which it moved with a retardation factor (Rr) of 0.11. This material was completely extracted into the chloroform phase of the extraction system of Folch et al. (24) , and analysis of everted sacs incubated in flavaspidic acid solutions indicated that all pigmented material so extracted moved with an Rr identical to that of the native compound, suggesting that it was not metabolized. No flavaspidic acid was detected in the aqueous phase. Advantage was taken of these properties of the compound, and its absorbancy peak at 350 nm to develop an assay for tissue flavaspidic acid concentration. Gut sacs were extracted by the method of Folch et al., and the lipid extract analyzed by thin-layer chromatography. The flavaspidic acid spot was identified, scraped, and eluted with chloroform: methanol (2: 1). Absorbancy was compared with a standard curve (flavaspidic acid in chloroform: methanol) and was corrected for a silica gel blank. The assay was linear over a wide range (0.001-0.1 ,&mol/ml); recovery from the silica gel was approximately 90%.
Radioactivity was assayed in a Beckman LS-250 liquid scintillation system (Beckman Instruments, Inc., Fullerton, Calif.). Aqueous samples were solubilized in a 10%o solution of Biosolv BBS-3 (Beckman Instruments, Inc.) in Liquifluor (New England Nuclear) and toluene.
Statistical methods. Significance of differences among experimental groups was determined by paired or unpaired t tests (25) .
RESULTS
Effect of flavaspidic acid and a-bromopalmitate on binding of oleate to FABP in vitro. Binding of [14C]-oleate to partially purified intestinal FABP fraction was estimated by gel chromatography (Methods). The significant and reversible inhibition of binding by flavaspidic acid and a-bromopalmitate are apparent (Fig. 1) . In other experiments, binding of flavaspidic acid to FABP was inhibited to a similar extent by equimolar oleate. These observations are consistent with the findings of Mishkin et al. (11) in studies of hepatic Z protein fraction. Significantly, although total recovery of ["C]oleate was greatly increased in the presence of albumin, this protein had little effect on the retention of ["C]oleate by FABP (13.4 vs. 10.1%), despite the fact that there were almost certainly many more unoccupied binding sites on albumin than on FABP under these conditions. Effect of flavaspidic acid and a-bromopalmitate on fatty acid uptake and utilization by everted jejunal sacs. As shown in Fig. 2 , neither flavaspidic acid nor a-bromopalmitate significantly affected oleate uptake. In contrast, both compounds markedly inhibited incorporation of oleate into triglyceride (Fig. 3) . Incorporation into other esterified lipids (phospholipids, diglycerides, and cholesterol ester) also was inhibited, but more variably and to a lesser degree (Table II) . Since these other lipids together account only for approximately 10% of the oleate esterified, and only 5-6% of mucosal uptake, the significance of changes in these minor fractions is difficult to interpret. Because of the overall decrease in esterification, however, ["C]oleate accumulated in the mucosa (Fig. 4) , suggesting that little if any fatty acid was diverted into oxidative pathways. In fact, oxidation of [1-"C]oleate to "CO also was significantly inhibited (Table III) Everted jejunal sacs were incubated in Krebs-Ringer bicarbonate medium lacking calcium and magnesium, and containing 5 mM glucose and mixed micelles, with or without flavaspidic acid or a-bromopalmitate. Fatty acid uptake was calculated from total lipid-extractable radioactivity in the sacs. Mean+SE; n =6 for controls and flavaspidic acid, n = 4 for a-bromopalmitate. Everted jejunal sacs were incubated in mixed micelles, with or without flavaspidic acid or a-bromopalmitate, as described in Fig. 1 and Methods. Lipids were extracted from sacs at the conclusion of the experiment, and analyzed for "4C after separation by thin-layer chromatography. Mean±+SE; n = 6 for controls and flavaspidic acid, n = 4 for a-bromopalmitate.
for less than 1% of the oleate taken up. Flavaspidic acid was taken up by everted sacs at approximately half the initial rate of ['4C]oleate (Fig. 5) . Saturation was nearly reached at 4 min, possibly due to its insignificant biotransformation, so that as tissue concentration gradually increased the medium-tissue diffusion gradient (upon which uptake depends) decreased. As shown in Table III , neither flavaspidic acid nor ca-bromopalmitate significantly inhibited "4COs production from acetate, while both compounds caused in- Incorporation of [E4C]oleate (1.8 mM in mixed micelles) into mucosal esters other than triglyceride was determined at 4 min as described in the legend to Fig. 4 . MeanLSE; n = 6 for control and flavaspidic acid; n = 4 for a-bromopalmitate. Fig. 1 and Methods. Lipids were extracted and analyzed for 1'C in triglycerides and fatty acids by thin-layer chromatography ( Fig. 2 and Methods). Mean+SE; n =6 for controls and flavaspidic acid, n = 4 for a-bromopalmitate. Sacs were extracted and assayed for flavaspidic acid content, as described in Methods. Mean±-SE; n=3-6. glycerol and fatty acid moieties), whereas incorporation into phospholipids was virtually unaffected. In Tables  III and IV , the effects of flavaspidic acid and a-bromopalmitate on [U-'4C]glucose incorporation into 14CO2 and lipids were studied on different occasions, and each is compared with its own control. Further evidence that flavaspidic acid did not irreversibly impair mucosal cell function is shown in Fig. 6 . In these studies, the effect of 1.8 mM flavaspidic acid on uptake of ["C]oleate and its incorporation into triglyceride by everted sacs was examined as a function of increasing micellar oleate concentration. At all oleate concentrations mucosal uptake was unaffected (Fig. 6A) . In the flavaspidic acid experiments (Fig. 6B) It is important to note that differences in oleate-dependent increase in mucosal triglyceride synthesis between control and inhibited sacs could not be explained by differences in mucosal ["4C]oleate. Thus (Fig. 6B) , an increase in micellar oleate from 1.8 to 7.2 mM did not significantly affect triglyceride synthesis in controls, whereas synthesis in the sacs incubated with flavaspidic acid nearly doubled. These divergent responses occurred despite (a) similar increments in mucosal ["4C]oleate concentrations under the two conditions (Fig. 6A) , and (b) similar mucosal uptakes of flavaspidic acid (237±41 nmol/g at 1.8 mM oleate; 205±+12 nmol/g at 7.2 mM oleate). These relationships suggest that in control sacs, the overall process of fatty acid esterification is "saturated" at relatively low oleate concentrations in medium and tissue. This and similar previous observations with linoleate and palmitate (16) suggest that one or more post-uptake steps in fatty acid absorption become rate limiting as luminal fatty acid concentrations increases. In contrast, with flavaspidic acid the incorporation of fatty acid into triglyceride is reversibly inhibited, so that "saturation" of this process is approached only at higher substrate concentrations.
Taken together, these experiments indicate that flavaspidic acid and a-bromopalmitate cause a relatively selective inhibition of fatty acid utilization at a stage after uptake, and at either or both of two sites: (a) in the endoplasmic reticulum, affecting fatty acid activation and(or) esterification; and(or) (b) the intracellular transfer of fatty acid which precedes activation. To resolve this question, the effects of flavaspidic acid and a-bromopalmitate on the microsomal fatty acid activating and esterifying enzymes were examined.
Effect of flavaspidic acid and a-bromopalmitate on acyl coenzyme A: monoglyceride acyltransferase activity in jejunal microsomes. Incorporation of ["4C] palmitoyl coenzyme A into diglyceride and triglyceride was examined in intestinal microsomes (Methods). It can be seen ( Table V) that neither flavaspidic acid nor a-bromopalmitate significantly inhibited activity, despite the fact that their concentrations were five times that of the substrate. Therefore, it is most unlikely that inhibition of triglyceride synthesis in everted sacs was due to an effect on monoglyceride acyltransferase. Furthermore, the lack of inhibition of [4C]palmitoyl CoA incorporation into triglyceride in these experiments suggests that Fig. 7 . Incubations were carried out under two conditions. In the first, a sonicated oleate emulsion in buffer was added to the incubation. In the second, the incubation included FABP fraction, 1.1 mg/ml (approximately 0.25 mg/ml FABP, i.e., 0.021 mM), or about one-third the concentration present in jejunal cytosol (2) . Enzyme activity was nearly linear over a wide range of substrate concentration, but was much greater in the presence of FABP. Possible explanations for this stimulatory effect include the following: (a) endogenous FABP-bound fatty acid was added to the incubation with FABP fraction, thereby increasing substrate concentration; (b) the FABP fraction contained activating enzyme; (c) the FABP complexed an inhibitor present in the microsomes; and (d) the FABP solubilized the fatty acid, or in some manner promoted enzyme-substrate interaction. Each of these possibilities was considered.
With regard to the first, the concentration of endogenous fatty acid in the FABP fraction was approximately equal to that of FABP on a mole basis, as noted in Methods. Thus, 1.1 mg/ml of FABP fraction would increase fatty acid concentration in the incubation by only 0.021 mM, an amount too small to account for the observed differences.
The second possibility, i.e., that FABP fraction contained active enzyme, is essentially excluded by the fact that no hydroxamate was formed in the absence of microsomes (unpublished observations).
The third possible explanation is that an inhibitor, present in the microsomes, was bound by the FABP fraction. Direct examination of this possibility is difficult, since the presence of significant quantities of fatty acid in the microsomes and uncertainties regarding actual "substrate" (presumably monomer) concentration preclude formal kinetic analysis of the data. Furthermore, the nature of this possible inhibitor is not apparent; fatty acid itself or acyl coenzyme A seem unlikely, since substrate concentrations as high as 0.8 mM had no detectable inhibitory effect (Fig. 7) and since all acyl CoA was immediately converted to the hydroxamate. Finally, the addition of albumin, which might also be expected to bind any potential inhibitor, failed to enhance ligase activity (Fig. 8) .
These considerations suggest that the fourth possibility is the most likely explanation for the effect of FABP on fatty acid: CoA ligase activity, i.e., that FABP favors the formation of the enzyme-substrate complex, probably via a physical effect on the oleate. Consistent with this concept is the finding that an even more pronounced (but presumably less specific) enhancement of ligase activity was observed when oleic acid was added to the system dispersed in a lecithin emulsion (Table VI) . The lecithin employed in these experiments was purified by silicic acid chromatography and did not contain detectable free fatty acids when analyzed by thin-layer chromatography. That the lecithin effect also was not attributable to contamination by fatty acid or to in vitro release of lecithin fatty acids by microsomal phospholipase is shown by control experi- At concentrations equal to that of oleic acid (0.1 mM), a-bromopalmitate and flavaspidic acid were only modestly inhibitory (Table VII) , and their effect was blunted when FABP fraction was added to the system. Neither inhibitor was activated to a significant extent (unpublished observations), a finding consistent with earlier observations of Pande et al. (26) in regard to a-bromopalmitate. The concentrations of inhibitor (0.1 mM) employed in these experiments is based on the estimated mean tissue concentration of flavaspidic acid present during the 4-min everted sac experiments (Fig.  5) ; tissue uptake of a-bromopalmitate could not be determined. In all probability, however, the actual cytosolic concentration of these inhibitors in the gut sac experiments was less than that employed in the microsomal studies, because of binding to cell membranes. It is likely, therefore, that these concentrations would overestimate the inhibitory effect of these compounds on the activating enzyme. On the basis of these experiments, it is reasonable to conclude that in the everted sacs, fatty acid activation was inhibited minimally or not at all by flavaspidic acid and a-bromopalmitate.
DISCUSSION
In the present studies, we investigated the role of FABP in intestinal fatty acid absorption, employing compounds which inhibit its reversible binding of long chain fatty acids. The findings clearly demonstrate that while flavaspidic acid and a-bromopalmitate did not affect uptake of oleate by everted jejunal sacs, they did inhibit fatty acid esterification to diglyceride and triglyceride, and oxidation to C02. The inhibition was not associated with a general depression of mucosal metabolism, and could not be explained by an effect on transacylation. Incorporation into phospholipid and cholesterol esters was affected to a lesser degree. This difference in the observed effect on incorporation into various lipid classes may reflect a change in overall fatty acid utilization, analogous to the observations of Ontko (27) in studies of isolated hepatocytes.
One possible explanation for the observed decrease in fatty acid esterification was that activation by fatty acid: CoA ligase in the endoplasmic reticulum was inhibited. It is of interest that activity of this enzyme was enhanced significantly in the presence of FABP fraction, probably due to an effect on enzyme-substrate interaction, since it could not be explained simply as "solubilization," e.g. by albumin. However, flavaspidic acid and a-bromopalmitate were only weak inhibitors of the activating enzyme (Table VII) , and this effect was blunted by FABP fraction at concentrations within the physiological range.
Thus, it is reasonable to conclude that in the everted sac experiments, flavaspidic acid and a-bromopalmitate Fatty Acid Binding Protein and Intestinal Absorption inhibited fatty acid esterification by intestinal absorptive cells at a stage after uptake, but before activation and transacylation in the endoplasmic reticulum. The only known event between cellular uptake and microsomal activation is the movement of fatty acid from the microvillus membrane to the endoplasmic reticulum. Since the inhibitors employed in these studies would not be expected to interfere with simple diffusion of fatty acid through an aqueous phase, it can be inferred that this translocation process depends on a somewhat more complex mechanism, the simplest model for which is the binding of long chain fatty acid to a soluble acceptor, i.e. FABP. The demonstrated inhibition of fatty acid binding to this protein by flavaspidic acid and a-bromopalmitate (Fig. 1) is consistent with this concept and can account for the effects of these compounds in the intact cell (everted sacs).
Thus, FABP may be viewed as an intracellular fatty acid transport protein. In addition, its enhancement of microsomal fatty acid: CoA ligase activity (Fig. 5) suggests that it also may promote the interaction of enzyme and substrate in this reaction. This effect appears to be relatively specific, since it is not observed when albumin is substituted for FABP.
A theoretical basis for the role of FABP in cellular fatty acid transport was considered earlier (2), and included the probability that long chain fatty acids were unlikely to desorb from the inner aspect of the microvillus membrane into the aqueous cytosol at a rate sufficiently rapid to account for observed rates of mucosal triglyceride synthesis. It was suggested that a soluble fatty acid acceptor (FABP) in the cytosol would facilitate this desorption. Recently, Sallee has provided evidence concerning the thermodynamics of long chain fatty acid permeation of the rat intestinal surface membrane (28) . His findings demonstrate that adsorption of long chain fatty acid monomer from an aqueous phase into the membrane is associated with an unexpectedly large decrease in free energy, implying that the membrane is highly nonpolar (29) . These findings imply, as a corollary, that fatty acid desorption at the cytosolic aspect of the membrane would require (in the absence of a soluble acceptor) an increase in free energy of similar magnitude; therefore, this process should indeed be facilitated to a significant extent by an acceptor in the aqueous phase.
Taken together, these different lines of evidence are consistent with, and more directly supportive of, the concept that intestinal FABP participates in the cytoplasmic transport and metabolism of absorbed long chain fatty acids. Recent studies in our laboratory suggest a similar role for hepatic FABP (30) . Also (Table III) . These differences, together with the fact that flavaspidic acid inhibition of oleate esterification was reversed by increasing oleate concentration (Fig. 6) suggest that uncoupling was not of major significance under the present conditions.
